08:00 , Dec 17, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Fas receptor (CD95) A study in mice and in human cell culture suggests that antagonizing CD95 in adipocytes could help treat obesity. Adipocytes...
07:00 , Oct 29, 2009 |  BC Innovations  |  Targets & Mechanisms

New autoimmunity targets

Apoptotic cell clearance has been posited as a potential strategy to help prevent autoimmunity, but so far it has not been clear how to modulate the process. Now, two research groups have described actual targets...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Clinical News

ARG098: Phase I started

Argenes began a Belgian Phase I trial to evaluate ARG098 injected into the patients' knee joint cavity. Argenes Inc. , Tokyo, Japan   Product: ARG098   Business: Autoimmune   Molecular target: NA   Description: Anti-Fas...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Clinical News

ARG098: Phase I start

By year end, Argenes will begin a dose-escalation, Japanese Phase I trial in patients. Argenes Inc. , Tokyo, Japan   Product: ARG098   Business: Autoimmune   Molecular target: NA   Description: Anti-Fas IgM monoclonal antibody...